Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2022

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Elodie Negre
  • Fonction : Auteur
Céline Mascaux
Denis Moro-Sibilot
François Pinquie
  • Fonction : Auteur
Alexis Cortot
Alexandra Langlais
Franck Morin

Résumé

Purpose - Methods - The IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with -mutated, advanced NSCLC who progressed after ≥ 1 platinum-based treatment were enrolled. Patients received pertuzumab at a loading dose of 840 mg and 420 mg thereafter; trastuzumab at an 8 mg/kg loading dose and 6 mg/kg thereafter; and docetaxel at a dose of 75 mg/m every 3 weeks. The primary outcome was the objective response rate (ORR). Other end points included the duration of response, progression-free survival, and safety (NCT03845270). Results - Forty-five patients were enrolled and treated. The median age was 64.5 years (range, 31-84 years), 35% were smokers, 72% were females, 15% had an Eastern Cooperative Oncology Group performance status of 2, and 30% had brain metastases. The objective response rate was 29% (n = 13), and 58% had stable disease (n = 26). The median progression-free survival was 6.8 months (95% CI, 4.0 to 8.5). The median duration of response in patients with a confirmed response (n = 13) was 11 months (95% CI, 2.9 to 14.9). Grade 3/4 treatment-related adverse events were observed in 64% of the patients. No patient discontinued treatment because of toxicity. The most frequent grade ≥ 3 treatment-related adverse events were neutropenia (33%), diarrhea (13%), and anemia (9%). Conclusion - Triple therapy with trastuzumab, pertuzumab, and docetaxel is feasible and effective for -mutated pretreated advanced NSCLC. These results highlight the effectiveness of the HER2 antibody-based strategy, which should be considered for these patients.
Fichier non déposé

Dates et versions

hal-03925605 , version 1 (05-01-2023)

Identifiants

Citer

Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, et al.. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology, 2022, 40 (7), pp.719-728. ⟨10.1200/JCO.21.01455⟩. ⟨hal-03925605⟩
41 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More